Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Northwest Biotherapeutics, Inc. (NWBO) had Return on Tangible Equity of 17.37% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$0.13M |
|
$-15.94M |
|
-- |
|
$0.13M |
|
$14.91M |
|
$-14.78M |
|
$-0.60M |
|
$-15.38M |
|
$-15.38M |
|
$-15.38M |
|
$-15.38M |
|
$-15.38M |
|
$-15.38M |
|
$-14.78M |
|
$-13.80M |
|
1.44B |
|
1.44B |
|
$-0.01 |
|
$-0.01 |
|
| Balance Sheet Financials | |
$6.16M |
|
$16.68M |
|
$23.39M |
|
$29.55M |
|
$83.92M |
|
$13.77M |
|
$32.26M |
|
$116.18M |
|
$-100.39M |
|
$-88.55M |
|
$-86.64M |
|
1.46B |
|
| Cash Flow Statement Financials | |
$-16.11M |
|
$-0.40M |
|
$24.18M |
|
$2.17M |
|
$4.32M |
|
$2.14M |
|
$0.75M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.07 |
|
-- |
|
-- |
|
-0.19 |
|
-0.64 |
|
100.00% |
|
-11281.68% |
|
-11281.68% |
|
-- |
|
-11738.93% |
|
-12166.41% |
|
$-16.50M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
15.32% |
|
|
Return on Tangible Equity |
17.37% |
-52.05% |
|
21.11% |
|
$-0.06 |
|
$-0.01 |
|
$-0.01 |
|